Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment.

Edén A, Fuchs D, Hagberg L, Nilsson S, Spudich S, Svennerholm B, Price RW, Gisslén M.

J Infect Dis. 2010 Dec 15;202(12):1819-25. doi: 10.1086/657342. Epub 2010 Nov 4.

2.

Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid.

Cusini A, Vernazza PL, Yerly S, Decosterd LA, Ledergerber B, Fux CA, Rohrbach J, Widmer N, Hirschel B, Gaudenz R, Cavassini M, Klimkait T, Zenger F, Gutmann C, Opravil M, Günthard HF; Swiss HIV Cohort Study.

J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):28-35. doi: 10.1097/QAI.0b013e318274e2b0. Erratum in: J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):e170-1.

PMID:
23018371
3.

Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy.

Yilmaz A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslén M.

J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):168-73.

4.

Asymptomatic Cerebrospinal Fluid HIV-1 Viral Blips and Viral Escape During Antiretroviral Therapy: A Longitudinal Study.

Edén A, Nilsson S, Hagberg L, Fuchs D, Zetterberg H, Svennerholm B, Gisslén M.

J Infect Dis. 2016 Dec 15;214(12):1822-1825. Epub 2016 Sep 28.

PMID:
27683820
5.

Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation.

Dahl V, Peterson J, Fuchs D, Gisslen M, Palmer S, Price RW.

AIDS. 2014 Sep 24;28(15):2251-8. doi: 10.1097/QAD.0000000000000400.

6.

Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.

Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG, Peytavin G, Tubiana R, Pialoux G, Katlama C.

Clin Infect Dis. 2010 Mar 1;50(5):773-8. doi: 10.1086/650538.

PMID:
20100092
7.

Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.

Tiraboschi JM, Muñoz-Moreno JA, Puertas MC, Alonso-Villaverde C, Prats A, Ferrer E, Rozas N, Maso M, Ouchi D, Martinez-Picado J, Podzamczer D.

HIV Med. 2015 Jul;16(6):388-92. doi: 10.1111/hiv.12243. Epub 2015 Feb 27.

8.

ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects.

Letendre SL, Mills AM, Tashima KT, Thomas DA, Min SS, Chen S, Song IH, Piscitelli SC; extended ING116070 study team.

Clin Infect Dis. 2014 Oct;59(7):1032-7. doi: 10.1093/cid/ciu477. Epub 2014 Jun 18.

9.

Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.

Yilmaz A, Verhofstede C, D'Avolio A, Watson V, Hagberg L, Fuchs D, Svennerholm B, Gisslén M.

J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):590-6. doi: 10.1097/QAI.0b013e3181f5b3d1.

PMID:
20847699
10.

Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.

Yilmaz A, Ståhle L, Hagberg L, Svennerholm B, Fuchs D, Gisslén M.

Scand J Infect Dis. 2004;36(11-12):823-8.

PMID:
15764168
11.

Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection.

Sinclair E, Ronquillo R, Lollo N, Deeks SG, Hunt P, Yiannoutsos CT, Spudich S, Price RW.

J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):544-52. doi: 10.1097/QAI.0b013e318162754f.

12.

Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load.

Peluso MJ, Ferretti F, Peterson J, Lee E, Fuchs D, Boschini A, Gisslén M, Angoff N, Price RW, Cinque P, Spudich S.

AIDS. 2012 Sep 10;26(14):1765-74. doi: 10.1097/QAD.0b013e328355e6b2.

13.

Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir.

Kravcik S, Gallicano K, Roth V, Cassol S, Hawley-Foss N, Badley A, Cameron DW.

J Acquir Immune Defic Syndr. 1999 Aug 15;21(5):371-5.

PMID:
10458617
14.

Cerebrospinal fluid viral load in HIV-1-infected patients without antiretroviral treatment: a longitudinal study.

Gisslén M, Hagberg L, Fuchs D, Norkrans G, Svennerholm B.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):291-5.

PMID:
9525428
15.

Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.

García F, Alonso MM, Romeu J, Knobel H, Arrizabalaga J, Ferrer E, Dalmau D, Ruiz I, Vidal F, Frances A, Segura F, Gomez-Sirvent JL, Cruceta A, Clotet B, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

J Acquir Immune Defic Syndr. 2000 Sep 1;25(1):26-35.

PMID:
11064501
16.

Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting.

Rawson T, Muir D, Mackie NE, Garvey LJ, Everitt A, Winston A.

J Infect. 2012 Sep;65(3):239-45. doi: 10.1016/j.jinf.2012.04.007. Epub 2012 Apr 17.

PMID:
22522289
17.

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.

Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Koletar SL, Johnson VA, Geiseler PJ, Daar ES; AIDS Clinical Trials Group Study A5202 Team.

N Engl J Med. 2009 Dec 3;361(23):2230-40. doi: 10.1056/NEJMoa0906768. Epub 2009 Dec 1.

18.

Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations.

Delille CA, Pruett ST, Marconi VC, Lennox JL, Armstrong WS, Arrendale RF, Sheth AN, Easley KA, Acosta EP, Vunnava A, Ofotokun I.

J Clin Pharmacol. 2014 Sep;54(9):1063-71. doi: 10.1002/jcph.298. Epub 2014 Apr 8.

20.

Cerebrospinal fluid viral load, virus isolation, and intrathecal immunoactivation in HIV type 2 infection.

Arvidson N, Gisslén M, Albert J, Brandin E, Svennerholm B, Fuchs D, Hagberg L.

AIDS Res Hum Retroviruses. 2004 Jul;20(7):711-5.

PMID:
15307916

Supplemental Content

Support Center